Oncolytics Biotech (ONCY) Operating Margin (2011 - 2017)
Oncolytics Biotech's (ONCY) quarterly Operating Margin came in at 0.0% in Q2 2017, down 36832.0% year-on-year from N/an in Q2 2016, and down 100.0% on a QoQ basis from 368.32% in Q2 2016.
Oncolytics Biotech (ONCY) Operating Margin (2011 - 2017) Analysis & Trends
Oncolytics Biotech (ONCY) has 3 years of Operating Margin data on file, last reported at 0.0% in Q2 2017.
- On a quarterly basis, Operating Margin fell 36832.0% year-over-year to 0.0% in Q2 2017; TTM through Jun 2017 was 0.0%, a 19622.0% decrease from a year earlier, with the FY2018 full-year figure at 97.36%, changed N/A from the prior year.
- Operating Margin for Q2 2017 stood at 0.0%, down from 368.32% in the prior quarter.
- Over the last five years, Operating Margin for ONCY reached as high as 368.32% in Q2 2016 and fell as low as 0.0% in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Oncolytics Biotech | 76.93 Mn | 76.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 0.00% |
| Jun 30, 2016 | 368.32% |
| Jun 30, 2011 | 471.50% |